<DOC>
	<DOCNO>NCT01078623</DOCNO>
	<brief_summary>The purpose multicenter , dose-ranging study compare two Fixed-Dose Combinations aclidinium bromide formoterol fumarate placebo , aclidinium bromide formoterol fumarate , administer BID patient stable , moderate severe COPD . Every treatment period 14-days long 7-days wash-out period . The trial start run phase 10 17-days duration end follow contact 14-days last treatment dose .</brief_summary>
	<brief_title>Efficacy Safety Two Fixed Dose Combinations Aclidinium Bromide With Formoterol Fumarate</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1 . Adult male nonpregnant , nonlactating female age 40 80 year old , inclusive . 2 . Patient clinical diagnosis stable moderate severe COPD accord GOLD classification 3 . Current , excigarette smoker smoke history least 10 packyears . 4 . Patient whose FEV1 Screening Visit measure 1015 minute post inhalation 400 mcg salbutamol 30 % FEV1 &lt; 80 % predict normal value ( i.e. , 100 x Postsalbutamol &lt; FEV1/ Predicted FEV1 must &lt; 80 % ≥ 30 % ) . 5 . Patient whose FEV1/FVC Screening Visit measure 1015 minute post inhalation 400 mcg salbutamol &lt; 70 % ( i.e. , 100 x Postsalbutamol FEV1 /FVC &lt; 70 % ) . 6 . Patient eligible able participate trial consent write purpose nature investigation explain . 7 . Patient whose COPD symptoms FEV1 value time randomisation stable compare Screening Visit , accord investigator 's medical judgment 1 . History current diagnosis asthma exerciseinduced bronchospasm . 2 . Clinically significant respiratory condition time Inform Consent signature 3 . Hospitalisation due COPD exacerbation within previous 3 month . 4 . Signs COPD exacerbation respiratory infection ( include upper respiratory tract ) within previous 6 week . 5 . Patient rest systolic blood pressure ≥ 200 mmHg , rest diastolic blood pressure ≥ 120 mmHg rest heart rate ≥ 105 bpm screen visit . 6 . Clinically significant cardiovascular condition 7 . Presence symptomatic prostatic hypertrophy and/or bladder neck obstruction . 8 . Presence narrowangle glaucoma . 9 . QTc [ calculate accord Bazett 's formula ( QTc=QT/RR1/2 ) 470 millisecond ECG perform Screening Visit , 10 . Patient maintain regular day/night , waking/sleeping cycle</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bronchitis</keyword>
	<keyword>Chronic</keyword>
	<keyword>Emphysema</keyword>
</DOC>